



http://pubs.acs.org/journal/acsodf Article

Preferential Solvation Study of the Synthesized Aldose Reductase Inhibitor (SE415) in the {PEG 400 (1) + Water (2)} Cosolvent Mixture and GastroPlus-Based Prediction

Afzal Hussain, Mohammad A. Altamimi, Obaid Afzal, Abdulmalik S. A. Altamimi, Abuzer Ali, Amena Ali, Fleming Martinez, Mohd Usman Mohd Siddique,* William E. Acree, Jr., and Abolghasem Jouyban



Cite This: ACS Omega 2022, 7, 1197-1210



Read Online


ACCESS I

III Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: (Z)-N-Benzyl-2- $\{2,4$ -dioxo-5- $\{4$ -prop-2-yl-1yloxyl)benzylidene)thiazolin-3-yl)}acetamide (SE415) is a novel aldose reductase inhibitor used in the management of diabetes mellitus (DM) and associated complications. Herein, the drug was solubilized (mole fraction solubility) in a "PEG 400 (polyethylene glycol 400) + water" mixture of various ratios at 298.15 K. We reported the preferential solvation of SE415 by PEG 400 using Kirkwood-Buff integrals, the thermodynamic functional parameter, in vitro dissolution, and GastroPlus-based predictions for in vivo performance. The result of Hansen solubility parameter analysis suggested PEG 400 as a suitable solvent for SE415 solubilization at 298.0 K, followed by prediction of several physicochemical



properties. In the preferential solvation study, the molar volume, Hildebrand solubility parameters, and the molecular radius of SE415 were estimated as 258.4 cm³·mol⁻¹, 27.62 MPa^{1/2}, and 0.468 nm, respectively, using Fedors' method. The inverse Kirkwood-Buff integrals indicated that the preferential solvation of SE415 by PEG 400 occurred in all studied ratios of the (PEG 400 + water) mixtures. The maximum value ($\delta x_{1,3} = 1.21 \times 10^{-2}$) of the preferential solvation of SE415 by PEG 400 was achieved at $x_1 = 0.15$. Then, using GastroPlus software, the maximum dissolution, improved in vivo oral absorption, and high regional compartmental absorption (total 99.0%) of SE415 in humans were predicted. Finally, the solubility data were correlated/predicted using various cosolvency models with satisfactory results. Thus, the binary cosolvent system can be a promising approach for enhanced oral absorption in controlling DM and associated complications in humans.

1. INTRODUCTION


Diabetes mellitus (DM) is a global health challenge as it is a complex metabolic disease (lack of insulin or insulin resistance) leading to high morbidity and mortality in developed nations. The aldose reductase (AR) is a key enzyme (cytoplasmic aldo-keto-reductase) of the polyol pathway that controls the critical factors involved in the onset, progression, and related DM complications (retinopathy, nephropathy, and neuropathy). The enzyme has been targeted for developing various AR inhibitors and is reported with challenged therapeutic effectiveness. Few commercial drugs (lidorestat, zopolrestat, fidarestat, and tolrestat) have been withdrawn from the market due to their low pharmacokinetics profile (due to their ionizable -COOH functional group).² Therefore, the newly synthesized potential benzylidine thiazolidinedione derivative, namely, (Z)-N-benzyl-2-{2,4-dioxo-5-(4prop-2-yl-1-yloxyl)benzylidene)thiazolin-3-yl)}acetamide (SE415), has been reported to target AR for managing longterm DM and associated complications. Moreover, the compound (SE415) is a potent PPARy (peroxisome proliferator-activated receptor gamma) modulator and AR inhibitor (dually active) (Siddique et al., 2021).³ In this study, SE415 is a chemically non-carboxylic acid inhibitor (Nsubstituted thiazolidinedione derivative) of the AR enzyme for dual functionality.³ The drug "SE415" (C₂₂H₁₈N₂O₄S) possessed poor water solubility (0.0059 mg/mL, at normal temperature and pressure, and pH 7.4) and adequate molar mass (406.0 g·mol⁻¹) and molar volume (258.4 cm³·mol⁻¹).³ The drug showed poor water solubility, which forced us to investigate a suitable co-solvent for maximized co-solvency and subsequently good dissolution rate in the phosphate buffer saline (PBS).

Several water-soluble solvents [ethanol, N-methyl-2-pyrrolidone (NMP), propylene glycol (PG), ethylene glycol (EG),

Received: October 15, 2021 Accepted: December 6, 2021 Published: January 2, 2022







FULL TEXT LINKS



ACS Omega. 2022 Jan 2;7(1):1197-1210. doi: 10.1021/acsomega.1c05788. eCollection 2022 Jan 11.

Preferential Solvation Study of the Synthesized Aldose Reductase Inhibitor (SE415) in the {PEG 400 (1) + Water (2)} Cosolvent Mixture and GastroPlus-Based Prediction

Afzal Hussain ¹, Mohammad A Altamimi ¹, Obaid Afzal ², Abdulmalik S A Altamimi ², Abuzer Ali ³, Amena Ali ⁴, Fleming Martinez ⁵, Mohd Usman Mohd Siddique ⁶, William E Acree Jr ⁷, Abolghasem Jouyban ⁸

Affiliations

Affiliations

- ¹ Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
- 2 Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al Kharj 11942, Saudi Arabia.
- 3 Department of Pharmacognosy, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
- ⁴ Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
- 5 Grupo de Investigaciones Farmacéutico-Fisicoquímicas, Departamento de Farmacia, Universidad Nacional de Colombia, Sede Bogotá, Cra 30 No. 45-03, Bogotá D. C. 111321, Colombia.
- Department of Pharmaceutical Chemistry, Shri Vile Parley Kelavani Mandal's Institute of Pharmacy, Dhule 424001, Maharastra, India.
- 7 Department of Chemistry, University of North Texas, Denton, Texas 76203-5017, United States.
- 8 Faculty of Pharmacy, Near East University, P.O. BOX: 99138 Nicosia, North Cyprus, Mersin 10, Turkey.

PMID: 35036782 PMCID: PMC8757459 DOI: 10.1021/acsomega.1c05788

Free PMC article

Abstract

(Z)-N-Benzyl-2-{2,4-dioxo-5-(4-prop-2-yl-1-yloxyl)benzylidene)thiazolin-3-yl)}acetamide (SE415) is a novel aldose reductase inhibitor used in the management of diabetes mellitus (DM) and associated complications. Herein, the drug was solubilized (mole fraction solubility) in a "PEG 400 (polyethylene glycol 400) + water" mixture of various ratios at 298.15 K. We reported the preferential solvation of SE415 by PEG 400 using Kirkwood-Buff integrals, the thermodynamic functional parameter, in vitro dissolution, and GastroPlus-based predictions for in vivo performance. The result of Hansen solubility parameter analysis suggested PEG 400 as a suitable solvent for SE415 solubilization at 298.0 K, followed by prediction of several physicochemical properties. In the preferential solvation study, the molar volume, Hildebrand solubility parameters, and the molecular radius of SE415 were estimated as 258.4 cm³·mol⁻¹, 27.62 MPa^{1/2}, and 0.468 nm, respectively, using Fedors' method. The inverse Kirkwood-Buff integrals indicated that the preferential solvation of SE415 by PEG 400 occurred in all studied ratios of the (PEG 400 + water) mixtures. The maximum value ($\delta x_{1,3} = 1.21 \times 10^{-2}$) of the preferential solvation of SE415 by PEG 400 was achieved at $x_1 = 0.15$. Then, using GastroPlus software, the maximum dissolution, improved in vivo oral absorption, and high regional compartmental absorption (total 99.0%) of SE415 in humans were predicted. Finally, the solubility data were correlated/predicted using various cosolvency models with satisfactory results. Thus, the

